Dr. Smith’s Diaper Rash Ointment named a 2014 NPP Awards Gold winner
SAN ANTONIO — Dr. Smith’s Diaper Rash Ointment has been named a 2014 National Parenting Publications Awards Gold winner in the Health & Home category, Mission Pharmacal reported Wednesday.
"With so many products on the market, it’s sometimes hard for moms and dads to find time to separate the truly great from the rest of the pack," stated Julie Kertes, NAPPA general manager. "Our testers save them that legwork by carefully evaluating hundreds of products and awarding only the best of the best."
"We are honored that Dr. Smith’s Diaper Rash Ointment has been recognized as a Gold winner by the National Parenting Publication Awards," stated Neill Walsdorf, Jr., president of Mission Pharmacal, the maker of Dr. Smith’s. "We make this product so that moms and dads can spend less time worrying about diaper rash and more time with their happy babies."
CDC updates polio vaccine recommendations
ATLANTA – The Centers for Disease Control and Prevention recently updated a health advisory, recommending an inactivated poliovirus booster for adults traveling to countries with an active wild polio virus in circulation.
These countries include Cameroon, Pakistan and the Syrian Arab Republic. The United States is not expected to issue any requirements for entry into the United States, however, according to the CDC.
According to reports, the CDC is aligning its vaccination recemmendation to that of the World Health Organization. As many as seven countries that have reported polio cases but have not exported the disease, including Afghanistan, Equatorial Guinea, Ethiopia, Iraq, Israel, Somalia and Nigeria, are encouraged to ensure polio vaccination boosters among residents and long-term travelers.
Upsher-Smith Laboratories gains approval for testosterone gel Vogelxo
MAPLE GROVE, Minn. – Upsher-Smith Laboratories on Wednesday announced that it has received final approval from the Food and Drug Administration for its new drug application for Vogelxo (testosterone) gel for topical use CIII.
Vogelxo is a Schedule CIII androgen indicated for testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired).
The company is preparing to launch Vogelxo in the near future, the company stated.